Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced that the company's self-developed PD-1/VEGF/CTLA-4 three-specific antibody CS2009 achieved a major clinical validation milestone, and announced the latest clinical data in the form of two quick oral reports at the 2026 European Society of Medical Oncology (ESMO) conference.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.